BruceA.CreeMD

Neuroimmunology/Multiple Sclerosis

Associate Clinical Professor, Neurology, UCSF School of Medicine

Dr. Cree is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1500 Owens St, Suite 320
San Francisco, CA 94158
Phone+1 415-353-2069

Fax+1 415-353-2633

Bruce Cree, MD, is a neurologist based in San Francisco, CA, specializing in neuroimmunology with a focus on multiple sclerosis. He completed his medical education (MD and Phd in Biochemistry) at the University of California San Francisco School of Medicine, an internship in internal medicine at California Pacific Medical Center, and a neurology residency at New York Presbyterian Hospital. Following residency he completed a fellowship in Neuroimmunology at the University of California San Francisco during which he earned a Masters in Advanced Studies in Clinical Research. He has contributed to over 300 peer-reviewed publications related to multiple sclerosis and other inflammatory diseases of the central nervous system such as neuromyelitis optica, optic neuritis and myelitis. He has engaged and led multiple clinical trials, serving as the principal investigator on studies involving treatments like ocrelizumab, inebilizumab, rituximab, ublituximab, fingolimod, ozanimod, siponimod, and tolebrutinib. Dr. Cree has been recognized as a Regional Top Doctor and achieved CMS Meaningful Use Stage 1 Certification. He currently serves as the Clinical Research Director in the Division of Neuroimmunology and Glial Biology in the Department of Neurology at the University of California San Francisco where he is a Professor of Clinical Neurology and is the George A. Zimmermann endowed Professor in Multiple Sclerosis.

New York Presbyterian Hospital (Cornell Campus)Residency, Neurology, 1998 - 2001
Sutter Health/California Pacific Medical CenterInternship, Internal Medicine, 1997 - 1998
University of California San Francisco School of MedicineClass of 1997

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

PubMed

Lectures

Optimizing the Risk-Benefit Therapeutic Equation for Multiple Sclerosis
CMEducation Resources, LLC, Pittsburgh, Pennsylvania - 5/4/2013
Optimizing the Risk-Benefit Therapeutic Equation for Multiple Sclerosis
CMEducation Resources, LLC, Cleveland, Ohio - 4/27/2013
Optimizing the Risk-Benefit Therapeutic Equation for Multiple Sclerosis
CMEducation Resources, LLC, Denver, Colorado - 4/20/2013
Optimizing the Risk-Benefit Therapeutic Equation for Multiple Sclerosis
CMEducation Resources, LLC, Saint Louis, Missouri - 4/13/2013
Optimizing the Risk-Benefit Therapeutic Equation for Multiple Sclerosis
CMEducation Resources, LLC, Memphis, Tennessee - 4/6/2013
Optimizing the Risk-Benefit Therapeutic Equation for Multiple Sclerosis
CMEducation Resources, LLC, Charlotte, North Carolina - 3/16/2013
Optimizing the Risk-Benefit Therapeutic Equation for Multiple Sclerosis
CMEducation Resources, LLC, Philadelphia, Pennsylvania - 3/9/2013
Optimizing the Risk-Benefit Therapeutic Equation for Multiple Sclerosis
CMEducation Resources, LLC, Houston, Texas - 3/2/2013
Optimizing the Risk-Benefit Therapeutic Equation for Multiple Sclerosis
CMEducation Resources, LLC, San Francisco, California - 2/23/2013
Join now to see all

Can Central Vein Sign Distinguish Multiple Sclerosis from Its Most Common Mimic?March 20th, 2025
Smoldering MS May Warrant Unique Diagnosis, Treatment, and Research StrategiesNovember 7th, 2024
How Progressive Multiple Sclerosis Differs from Relapsing-Remitting MSAugust 27th, 2024
Join now to see all